Alan Bash - 24 Jul 2026 Form 3 Insider Report for Legend Biotech Corp (LEGN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
03 Aug 2026, 17:02:00 UTC
Prior SEC filing
31 May 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Robert Staloff, Attorney-in-Fact

Key filing fact

Alan Bash filed Form 3 for Legend Biotech Corp (LEGN) on 03 Aug 2026.

Key facts

  • This page summarizes Alan Bash's Form 3 filing for Legend Biotech Corp (LEGN).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 03 Aug 2026, 17:02.

Change

  • Previous filing in this sequence was filed on 31 May 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001908421 Primary reporting owner

BASH ALAN

Relationship
Interim CEO
Address
C/O LEGEND BIOTECH CORP, 2101 COTTONTAIL LANE, SOMERSET
Signature
/s/ Robert Staloff, Attorney-in-Fact
Signature date
03 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LEGN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
30,234
Date
24 Jul 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

Footnote F2

Includes 13,092 restritcted share units (the "RSUs") for which the performance criteria was previously determined to have been satisfied and which will vest on 12/20/2026, subject to the Reporting Person's continued service to the Issuer on such vesting date. Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .